Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating adverse events and changes in disease activity of oral ABBV-453, given alone or with subcutaneous and/or oral antimyeloma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ABBV-453

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING